FT-001

CAS No. 1778655-51-8

FT-001( FT001 )

Catalog No. M12678 CAS No. 1778655-51-8

FT-001 is a novel potent, orally acitve inhibitor of BET bromodomain with IC50 of 0.1 uM for BRD4 BD1.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 299 In Stock
2MG 166 In Stock
5MG 255 In Stock
10MG 374 In Stock
25MG 562 In Stock
50MG 770 In Stock
100MG 1051 In Stock
200MG Get Quote In Stock
500MG 2102 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    FT-001
  • Note
    Research use only, not for human use.
  • Brief Description
    FT-001 is a novel potent, orally acitve inhibitor of BET bromodomain with IC50 of 0.1 uM for BRD4 BD1.
  • Description
    FT-001 is a novel potent, orally acitve inhibitor of BET bromodomain with IC50 of 0.1 uM for BRD4 BD1; inhibits the expression of MYC in the MV-4-11 cell line with IC50 of 0.46 uM, shows anti-proliferative activity with IC50 of 0.22 uM; displays complete tumor growth inhibition in mouse MV-4-11 xenograft model.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    FT001
  • Pathway
    Chromatin/Epigenetic
  • Target
    Bromodomain
  • Recptor
    Bromodomain
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1778655-51-8
  • Formula Weight
    467.584
  • Molecular Formula
    C25H29N3O4S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC(N1[C@@H](C)CN(C(C2CC2)=O)C3=C1C=CC(C4=CC=C(N(CC5)CCS5(=O)=O)C=C4)=C3)=O
  • Chemical Name
    (S)-1-(4-(cyclopropanecarbonyl)-6-(4-(1,1-dioxidothiomorpholino)phenyl)-2-methyl-3,4-dihydroquinoxalin-1(2H)-yl)ethan-1-one

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Millan DS, et al. ACS Med Chem Lett. 2017 Jul 14;8(8):847-852.
molnova catalog
related products
  • BETi-211

    A novel potent small-molecule BET bromodomain (BRD) inhibitor that binds to BET proteins with Ki values of <1 nM.

  • CeMMEC2

    CeMMEC2 is a novel potent BRD4 inhibitor with IC50 of 0.9 uM.

  • RVX2135

    RVX2135 is a novel potent and orally bioavailable inhibitor of Brd2, Brd3, Brd4, and BrdT.